Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

URSO-panacea or placebo?

J Neuberger1

  • 1Liver Unit Queen Elizabeth Hospital Birmingham, UK.

Hepatology (Baltimore, Md.)
|March 25, 2000
PubMed
Summary
This summary is machine-generated.

Ursodeoxycholic acid (UDCA) shows no significant benefit for primary biliary cirrhosis (PBC) progression or survival in randomized trials. Its established role as standard therapy for PBC requires re-evaluation based on current evidence.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The effect on consent rates for deceased organ donation in Wales after the introduction of an opt-out system.

Anaesthesia·2020
Same author

Editorial: covert hepatic encephalopathy-silent but serious.

Alimentary pharmacology & therapeutics·2018
Same author

Confirmation of specificity of reactivity in a solid phase ELISA for the detection of hepatitis E viral antigen improves utility of the assay.

Journal of virological methods·2017
Same author

Donors With Immune Thrombocytopenia: Do They Pose a Risk to Transplant Recipients?

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2016
Same author

The inter-relationship of symptom severity and quality of life in 2055 patients with primary biliary cholangitis.

Alimentary pharmacology & therapeutics·2016
Same author

2016 Comprehensive Update of the Banff Working Group on Liver Allograft Pathology: Introduction of Antibody-Mediated Rejection.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2016
Same journal

Decoding fibrosis: Transcriptomic and clinical insights via AI-derived collagen deposition phenotypes in MASLD.

Hepatology (Baltimore, Md.)·2026
Same journal

A randomized controlled trial of stepped treatment to reduce unhealthy alcohol use in patients with chronic liver disease.

Hepatology (Baltimore, Md.)·2026
Same journal

AASLD AST NASPGHAN Practice Guideline on pediatric liver transplantation: Candidate evaluation.

Hepatology (Baltimore, Md.)·2026
Same journal

H4K12 lactylation drives TREM2high macrophages differentiation in liver fibrosis.

Hepatology (Baltimore, Md.)·2026
Same journal

Good vibrations: Using VCTE to predict hepatic decompensation in MASLD.

Hepatology (Baltimore, Md.)·2026
Same journal

One size does not fit all: Global variability in noninvasive testing for MASLD.

Hepatology (Baltimore, Md.)·2026
See all related articles

Area of Science:

  • Hepatology
  • Clinical Trials
  • Systematic Reviews

Background:

  • Primary biliary cirrhosis (PBC) is an autoimmune liver disease.
  • Ursodeoxycholic acid (UDCA) is the sole approved treatment for PBC.
  • The efficacy of UDCA in halting PBC progression remains uncertain.

Purpose of the Study:

  • To systematically evaluate the therapeutic benefits of UDCA in patients with PBC.
  • To clarify the impact of UDCA on disease progression and patient outcomes.

Main Methods:

  • A systematic review and meta-analysis of randomized controlled trials (RCTs) and switch-over studies.
  • Searches of Medline, Embase, review articles, and conference abstracts.
  • Inclusion of trials with >6 months follow-up in PBC patients meeting diagnostic criteria.

Related Experiment Videos

Main Results:

  • 17 studies (11 RCTs, 6 switch-over) involving 1272 patients were analyzed.
  • UDCA improved liver biochemistry but not symptoms or histological progression.
  • Meta-analysis revealed no significant differences in death, liver transplantation, or complications between UDCA and placebo.

Conclusions:

  • Current randomized controlled trials do not provide evidence for UDCA's therapeutic benefit in PBC.
  • The established use of UDCA as standard PBC therapy warrants re-examination.